Gallant key facts
as of Oct 2026- Developer of a pet health technology platform designed to deliver regenerative stem cell therapies for improved veterinary care.
- Gallant is valued at approximately $72.0M as of Oct 2026 (last reported valuation).
- It has raised $60.5M; the latest was Later Stage VC ($18.0M) in Jun 2025.
- Notable investors include Alumni Ventures, Unpopular Ventures, Slow Ventures, Bling Capital, Digitalis Ventures — 23 tracked in total.
- Status: Privately Held (backing).
Gallant's last reported valuation, Jun 2025. Nothing priced has surfaced since.
- ·The complete investor list: 23 names
- ·Watch Gallant: the Monday email on marks, rounds and moves
Gallant funding rounds
No funding rounds for Gallant are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Gallant
23+Gallant valuation
Gallant's last reported valuation was $72 million in Jun 2025. No priced round, secondary trade or fund mark has surfaced since.
Gallant investors
23 investors are on record for Gallant, including Alumni Ventures, Unpopular Ventures, Slow Ventures and Bling Capital. By type, the record holds 7 venture capital firms, 2 family offices and 1 private equity firm.
About Gallant
Developer of a pet health technology platform designed to deliver regenerative stem cell therapies for improved veterinary care. The company's platform offers standardized stem cell banking, allogeneic treatments, and controlled field trials of off-the-shelf stem cell therapies grounded in scalable science, enabling veterinarians in primary care settings to provide improved treatment options and better health outcomes for companion animals.
- Sector
- Business Products and Services (B2B)
- HQ
- San Diego, CA, United States
- Founded
- 2018
- Employees
- 50
- Website
- gallant.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.